Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer’s disease

  • M. S. Cheon
  • S. H. Kim
  • M. Fountoulakis
  • G. Lubec
Part of the Journal of Neural Transmission Supplement 67 book series (NEURAL SUPPL, volume 67)


Fatty acid binding proteins (FABPs) are thought to play a role in the binding, targeting and transport of long-chain fatty acids, and at least three types of FABPs are found in human brain; heart type (H)-FABP, brain type (B)-FABP and epidermal type (E)-FABP. Although all three FABPs could be involved in normal brain function in prenatal and postnatal life, a neurobiological role of FABPs in neurodegenerative diseases has not been reported yet. These made us evaluate the protein levels of FABPs in brains from patients with Down syndrome (DS) and Alzheimer’s disease (AD) and fetal cerebral cortex with DS using two-dimensional (2-D) gel electrophoresis with subsequent matrix-assisted laser desorption ionization mass spectroscopy (MALDI-MS) identification and specific software for quantification of proteins. In adult brain, B-FABP was significantly increased in occipital cortex of DS, and H-FABP was significantly decreased in DS (frontal, occipital and parietal cortices) and AD (frontal, temporal, occipital and parietal cortices). In fetal brain, B-FABP and epidermal E-FABP levels were comparable in controls and DS. We conclude that aberrant expression of FABPs, especially H-FABP may alter membrane fluidity and signal transduction, and consequently could be involved in cellular dysfunction in neurodegenerative disorders.


Down Syndrome Fatty Acid Binding Protein Down Syndrome Patient Heart Type Fatty Acid Binding Protein Laser Desorption Ionization Mass Spectroscopy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Alzheimer’s disease


Down syndrome


fatty acid


fatty acid binding protein


polyunsaturated fatty acid


two dimensional


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bass NM, Raghupathy E, Rhoads DE, Manning JA, Ockner RK (1984) Partial purification of molecular weight 12,000 fatty acid binding proteins from rat brain and their effect on synaptosomal Na+ dependent amino acid uptake. Biochem 23: 6539–6544CrossRefGoogle Scholar
  2. Bendt P, Hobohm U, Langen H (1999) Reliable automatic protein identification from matrix-associated laser desorption/ionization mass spectrometric peptide fingerprints. Electrophoresis 20: 3521–3526CrossRefGoogle Scholar
  3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254PubMedCrossRefGoogle Scholar
  4. Brooksbank BW, Balazs R (1984) Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down’s syndrome fetal brain. Brain Res 318: 37–44PubMedGoogle Scholar
  5. Brooksbank BW, Martinez M (1989) Lipid abnormalities in the brain in adult Down’s syndrome and Alzheimer’s disease. Mol Chem Neuropathol 11: 157–185PubMedCrossRefGoogle Scholar
  6. Brooksbank BW, Walker D, Balazs R, Jorgensen OS (1989) Neuronal maturation in the foetal brain in Down’s syndrome. Early Hum Dev 18: 237–246PubMedCrossRefGoogle Scholar
  7. Fountoulakis M, Langen H (1997) Identification of protein by matrix-assisted laser desorption ionization-mass spectroscopy following in-gel digestion in low-salt nonvolatile buffer and simplified peptide recovery. Anal Biochem 250: 153–156PubMedCrossRefGoogle Scholar
  8. Greber-Platzer S, Schatzmann-Turhani D, Cairns N, Balcz B, Lubec G (1999) Expression of the transcription factor ETS2 in brain of patients with Down syndrome-evidence against the overexpression-gene dosage hypothesis. J Neural Transm [Suppl] 57: 269–281Google Scholar
  9. Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 58: 740–747PubMedCrossRefGoogle Scholar
  10. Krapfenbauer K, Yoo BC, Kim SH, Cairns N, Lubec G (2001) Differential display reveals downregulation of the phospholipid transfer protein ( PLTP) at the mRNA level in brains of patients with Down syndrome. Life Sci 68: 2169–2179PubMedCrossRefGoogle Scholar
  11. Kurz A, Zimmer A, Schnutgen F, Bruning G, Spener F, Muller T (1994) The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. Development 120: 2637–2649Google Scholar
  12. Labudova O, Krapfenbauer K, Moenkemann H, Rink H, Kitzmuller E, Cairns N, Lubec G (1998) Decreased transcription factor junD in brains of patients with Down syndrome. Neurosci Lett 252: 159–162PubMedCrossRefGoogle Scholar
  13. Langen H, Roeder D, Juranville JF, Fountoulakis M (1997) Effect of the protein application mode and the acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis 18: 2085–2090PubMedCrossRefGoogle Scholar
  14. Langen H, Berndt P, Roder D, Cairns N, Lubec G, Fountoulakis M (1999) Two-dimensional map of human brain proteins. Electrophoresis 20: 907–916PubMedCrossRefGoogle Scholar
  15. Liu Y, Long LD, De Leon M (2000) In situ and immunocytochemical localization of EFABP mRNA and protein during neuronal migration and differentiation in the rat brain. Brain Res 852: 16–27PubMedCrossRefGoogle Scholar
  16. Mirra SS, Heyman A, McKeel D, Sumi S, Crain BJ (1991) The consortium to establish a registry for Alzheimer’s disease. Neurology 41: 479–486PubMedCrossRefGoogle Scholar
  17. Myers-Payne SC, Hubbell T, Pu L, Schnutgen F, Borchers T, Wood WG, Spener F, Schroeder F (1996) Isolation and characterization of two fatty acid binding proteins from mouse brain. J Neurochem 66: 1648–1656PubMedCrossRefGoogle Scholar
  18. Owada Y, Yoshimoto T, Kondo H (1996) Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains J Chem Neuroanat 12: 113–122PubMedCrossRefGoogle Scholar
  19. Petrou S, Ordway RW, Singer JJ, Walsh JV Jr (1993) A putative fatty acid-binding domain of the NMDA receptor. Trends Biochem Sci 18: 41–42PubMedCrossRefGoogle Scholar
  20. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR (1998) Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res 23: 81–88PubMedCrossRefGoogle Scholar
  21. Pu L, Igbavboa U, Wood WG, Roths JB, Kier AB, Spener F, Schroeder F (1999) Expression of fatty acid binding proteins is altered in aged mouse brain. Mol Cell Biochem 198: 69–78PubMedCrossRefGoogle Scholar
  22. Richieri GV, Ogata RT, Kleinfeld AM (1994) Equilibrium constants for the binding of fatty acids with fatty acid binding proteins from adipocytes, intestine, heart, and liver measured with the fluorescent probe ADIFAB. J Biol Chem 269: 23918–23930PubMedGoogle Scholar
  23. Shimizu F, Watanabe TK, Shinomiya H, Nakamura Y, Fujiwara, T (1997) Isolation and expression of a cDNA for human brain fatty acid-binding protein (B-FABP). Biochim Biophys Acta 1354: 24–28PubMedGoogle Scholar
  24. Sikora E, Radziszewska E, Kmiec T, Maslinska D (1993) The impaired transcription factor AP-1 DNA binding activity in lymphocytes derived from subjects with some symptoms of premature aging. Acta Biochim Pol 40: 269–272PubMedGoogle Scholar
  25. Tierney MC, Fisher RH, Lewis AJ, Torzitto ML, Snow WG, Reid DW, Nieuwstraaten P, Van Rooijen LAA, Derks HJGM, Van Wijk R, Bischop A (1988) The NINCDAADRDA work group criteria for the clinical diagnosis of probable Alzheimer’s disease. Neurology 38: 359–364PubMedCrossRefGoogle Scholar
  26. Veerkamp JH, Paulussen RJ, Peeters RA, Maatman RG, van Moerkerk HT, van Kuppevelt TH (1990) Detection, tissue distribution and (sub)cellular localization of fatty acid-binding protein types. Mol Cell Biochem 98: 11–18PubMedCrossRefGoogle Scholar
  27. Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G (2001) Decreased brain levels of 2’, 3’cylic nucleotide-3’-phosphodiesterase in Down syndrome and Alzheimer’s disease. Neurobiol Aging 22: 547–553PubMedCrossRefGoogle Scholar
  28. Wells K, Farooqui AA, Liss L, Horrocks LA (1995) Neural membrane phospholipids in Alzheimer disease. Neurochem Res 20: 1329–1333PubMedCrossRefGoogle Scholar
  29. Yeghiazaryan K, Turhani-Schatzmann D, Labudova O, Schuller E, Olson EN, Cairns N, Lubec G (1999) Downregulation of the transcription factor scleraxis in brain of patients with Down syndrome. J Neural Transm [Suppl] 57: 305–314Google Scholar
  30. Yehuda S, Rabinovitz S, Mostofsky DI (1999) Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res 56: 565–570PubMedCrossRefGoogle Scholar
  31. Yoo BC, Cairns N, Fountoulakis M, Lubec G (2001) Synaptosomal proteins, beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP), gamma-SNAP and synaptotagmin I in brain of patients with Down syndrome and Alzheimer’s disease. Dement Geriatr Cogn Disord 12: 219–225PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • M. S. Cheon
    • 1
  • S. H. Kim
    • 1
  • M. Fountoulakis
    • 2
  • G. Lubec
    • 1
    • 3
  1. 1.Department of PediatricsUniversity of ViennaAustria
  2. 2.F. Hoffmann-La Roche, Ltd.BaselSwitzerland
  3. 3.CChem, FRSC (UK), Department of PediatricsUniversity of ViennaViennaAustria

Personalised recommendations